Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948342 | 0.89 | GPR119 (0.52) | GPR119FAAHF10KDM4EPKM | |
| SCHEMBL947729 | 0.88 | FAAH (0.56) | GPR119FAAHF10KDM4EPKM | |
| SCHEMBL949421 | 0.86 | FAAH (0.54) | GPR119FAAHF10 | |
| SCHEMBL947643 | 0.86 | FAAH (0.48) | GPR119FAAHKDM4EPKMOPRD1 | |
| SCHEMBL6151661 | 0.84 | KDM4E (0.52) | GPR119FAAHKDM4EPKMOPRD1 | |
| SCHEMBL15514971 | 0.82 | F10 (0.52) | F10KDM4EOPRD1 | |
| SCHEMBL31114285 | 0.81 | JAK3 (0.48) | GPR119KDM4EOPRD1OPRK1 | |
| SCHEMBL948139 | 0.79 | GPR119 (0.53) | GPR119FAAHKDM4E | |
| SCHEMBL949087 | 0.78 | GPR119 (0.50) | GPR119FAAHKDM4EPKMOPRD1 | |
| SCHEMBL948688 | 0.77 | FAAH (0.54) | GPR119FAAHKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188642-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-10188642-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| EP-2892890-B1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| EP-2892890-B1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| US-9334286-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9334286-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9334286-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| WO-2014037751-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | GPR119 1327/4885FAAH 1246/4885F10 545/4885 |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | BUB1B, BUB1, PLK1 | GPR119 2051/4885FAAH 4806/4885F10 4147/4885 |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | BUB1B, BUB1, PLK1 | GPR119 2051/4885FAAH 4806/4885F10 4147/4885 |
| US-10188642-B2 | Pharmacologically active compounds | BUB1B, BUB1, PLK1 | GPR119 2051/4885FAAH 4806/4885F10 4147/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | GPR119 1118/4885FAAH 1524/4885F10 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.